Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05642312 · ClinicalTrials.gov registry record · Phase 3
A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema
A Phase 3 study of Uveitic Macular Edema, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT05642312 is a Phase 3 study of Uveitic Macular Edema that has completed, run by Hoffmann-La Roche. The registered enrollment target is 245 participants. The trial reports 20 study locations across 16 states.
The verdict
NCT05642312, a Phase 3 study of Uveitic Macular Edema, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
Conditions Studied
Interventions
- OTHER Sham
- DRUG Vamikibart
Study Locations (20)
Other
- LKH-Univ.Klinikum Graz - Graz
- Kepler Universitätskliniken GmbH - Med Campus III - Linz
- Medizinische Universitat Wien - Vienna
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- The Ohio State University Investigational Drug Services - Columbus
Texas
- Austin Clinical Research LLC - Austin
- Texas Retina Associates - Dallas
California
- Kaiser Permanente Southern California - Los Angeles
Colorado
- Colorado Retina Associates, PC - Lakewood
Florida
- Retina Vitreous Associates of Florida - St. Petersburg
Maryland
- Cumberland Valley Retina PC - Hagerstown
Minnesota
- VitreoRetinal Surgery, PLLC. - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2025-07-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05642312
The ClinicalTrials.gov registry entry for NCT05642312 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 245 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveitic Macular Edema appearing as the primary indexed condition, and to 2 interventions - of which Sham is the first listed.
NCT05642312 reports 20 study locations spanning 16 distinct geographic areas - top geographies include Other, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT05642312 about?
NCT05642312 is a clinical study titled "A Study to Investigate Vamikibart in Participants With Uveitic Macular Edema". This study will assess the efficacy and safety of vamikibart in participants with uveitic macular edema.
What is the current status of trial NCT05642312?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 245 participants. The study started on 2023-01-09. Estimated completion is 2025-07-09.
What conditions does trial NCT05642312 study?
This clinical trial studies the following conditions: Uveitic Macular Edema.
What interventions are being tested in trial NCT05642312?
The interventions under investigation include: Sham (OTHER), Vamikibart (DRUG).
Who is sponsoring clinical trial NCT05642312?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05642312 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.